Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.

× No keyword cloud information.

28 in total

1. Infliximab for the treatment of fistulas in patients with Crohn's disease.

Authors: D H Present; P Rutgeerts; S Targan; S B Hanauer; L Mayer; R A van Hogezand; D K Podolsky; B E Sands; T Braakman; K L DeWoody; T F Schaible; S J van Deventer
Journal: N Engl J Med Date: 1999-05-06 Impact factor: 91.245

2. CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

Authors: A P DICK; M J GRAYSON; R G CARPENTER; A PETRIE
Journal: Gut Date: 1964-10 Impact factor: 23.059

3. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors: S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal: N Engl J Med Date: 1997-10-09 Impact factor: 91.245

4. Long-term evolution of gut inflammation in patients with spondyloarthropathy.

Authors: M De Vos; H Mielants; C Cuvelier; A Elewaut; E Veys
Journal: Gastroenterology Date: 1996-06 Impact factor: 22.682

5. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study.

Authors: D O Clegg; D J Reda; M Abdellatif
Journal: Arthritis Rheum Date: 1999-11

6. Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo.

Authors: T J Smeets; M C Kraan; J Versendaal; F C Breedveld; P P Tak
Journal: J Rheumatol Date: 1999-10 Impact factor: 4.666

Review 7. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis.

Authors: A F Kavanaugh
Journal: Rheum Dis Clin North Am Date: 1998-08 Impact factor: 2.670

8. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects.

Authors: H Mielants; E M Veys; C Cuvelier; M De Vos; S Goemaere; L De Clercq; L Schatteman; D Elewaut
Journal: J Rheumatol Date: 1995-12 Impact factor: 4.666

Review 9. Methotrexate use in psoriasis and psoriatic arthritis.

Authors: M L Cuellar; L R Espinoza
Journal: Rheum Dis Clin North Am Date: 1997-11 Impact factor: 2.670

10. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study.

Authors: A Spadaro; V Riccieri; A Sili-Scavalli; F Sensi; E Taccari; A Zoppini
Journal: Clin Exp Rheumatol Date: 1995 Sep-Oct Impact factor: 4.473

4 in total

1. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.

Authors: A Boonen; D van der Heijde; J L Severens; A Boendermaker; R Landewé; J Braun; J Brandt; J Sieper; Sj van der Linden
Journal: Ann Rheum Dis Date: 2005-07-13 Impact factor: 19.103

Review 2. Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment options.

Authors: Eric Toussirot; Daniel Wendling
Journal: Drugs Aging Date: 2005 Impact factor: 3.923

3. Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis.

Authors: A Croce; O Firuzi; F Altieri; M Eufemi; R Agostino; R Priori; M Bombardieri; C Alessandri; G Valesini; L Saso
Journal: J Clin Lab Anal Date: 2007 Impact factor: 2.352

Review 4. Management of ankylosing spondylitis with infliximab.

Authors: Éric Toussirot; Ewa Bertolini; Daniel Wendling
Journal: Open Access Rheumatol Date: 2009-06-17

4 in total